Bayer shutters St. Joseph ops, idling 130 workers; Warner Chilcott beats Bayer's patent infringement claims;

@FiercePharma: Think the pharma M&A party will start winding down? Think again. Item | Follow @FiercePharma

@EricPFierce: Chinese API maker Yunnan Hande Bio-Tech gets a second FDA warning letter. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Perrigo spurned Mylan's $29B offer, but would a bigger one do? Story | Follow @CarlyHFierce

> After failing to find a buyer, Bayer has decided to close its St. Joseph, MO, animal health products manufacturing operations and idle 130 employees. Report

> Two psychiatrists at a Texas state hospital have resigned after being told they would face disciplinary actions for accepting hundreds of thousands of dollars in speaking and consulting fees from AstraZeneca ($AZN) while also promoting one of its drugs to state officials. More

> Warner Chilcott, now owned by Actavis, Tuesday prevailed over Bayer's accusations that it infringed a patent for the latter's oral contraceptive Yaz. Report (sub. req.)

> Sun Pharma says its founder, Dilip Shanghvi, has not bought shares in its Daiichi Sankyo deal. Report

Medical Device News

@FierceMedDev: WuXi and DNAnexus join up for cloud-based genomic services. News | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Study finds Boston Scientific's S-ICD has sterling safety profile, quarterly sales exceed $100M. Report | Follow @VarunSaxena2

@EmilyWFierce: FBI admits to decades of flawed hair analysis. Washington Post story | Follow @EmilyWFierce

> Google-backed telemedicine company raises $15M to support its Spruce app. Item

> Medtronic touts the first neurostimulator to get approval for use during full-body MRI scan. Report

Biotech News

@FierceBiotech: Salk heavyweight Evans raising $33M for an intriguing stealth biotech. Report | Follow @FierceBiotech

@JohnCFierce: Re-patients. I'm not buying the "you're a cynic" response. Manipulating patients for commercial gain and PR cover is SOP in biopharma. | Follow @JohnCFierce

> Almirall spares 9 jobs as ax falls on Spanish R&D operation. Report

> MaxCyte buys into CAR-T with Johns Hopkins partnership. Item

> Allied Minds' SciFluor banks $30M to get into the clinic. Article

Biotech Research News

> AbbVie, Infinity tout preclinical evidence of a cancer combo's potential. Story

> MD Anderson takes experimental lung cancer drug into the clinic. Report

> Seeking a drug cocktail, CSHL team points to a new pathway for breast cancer. More

> Yale cancer group refines an antibody approach to targeting cancer cells. Story

> Small European study highlights promise of gene therapy for rare immune disease. Article

Diagnostics News

> LabCorp rides direct-to-consumer wave with online testing services. More

> Quest joins forces with French health agency for BRCA research initiative. Report

> Cardinal Health pays feds $26M to settle charges of monopolizing molecular imaging agent market. Story

> Color Genomics unveils $249 spit test for breast and ovarian cancer. Item

> Focus Diagnostics gets FDA nod for rapid strep test. Article

Pharma Marketing News

> Attention pharma laggards: FitBit trackers delivered in Biogen's MS movement study. News

> How to make sure DTC doesn't turn off patients? Ask them to tailor your ads. Article

> Pharma's getting savvier about social, with Boehringer, Bayer leading the pack. More

> Pfizer's Lyrica team matches the spokesman to the message. Story

> Merck aims for double payoff with new diabetes education push. Article

And Finally... A new BMJ editorial debunks serotonin's role in depression, calling it a "marketing myth." More

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.